Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50

Reuters

Sep 30

Parmantier & Cie. Initiates 'Buy' Rating on <a href="https://laohu8.com/S/CUV.AU">Clinuvel Pharmaceuticals</a> Limited, Sets 12-Month Price Target at AU$26.50

Parmantier & Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a "Buy" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier & Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23628), on September 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2571531763"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571531763\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571531763?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 16:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571531763","market":"us","top_or_hot":-1,"title":"Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Parmantier &amp; Cie. Initiates 'Buy' Rating on <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> Limited, Sets 12-Month Price Target at AU$26.50\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Parmantier &amp; Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier &amp; Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23628), on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 16:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Parmantier &amp; Cie. Initiates 'Buy' Rating on <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> Limited, Sets 12-Month Price Target at AU$26.50\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Parmantier &amp; Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier &amp; Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23628), on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CUV.AU","symbol_name":"CLINUVEL PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL9fPGnt:1","article_id":"2571531763","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571531763","pubTimestamp":1759222345,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Parmantier & Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier & Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"帕尔曼蒂埃公司。对Clinuvel Pharmaceuticals Limited给予“买入”评级，将12个月目标价定为26.50澳元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":0.9},"content_text":"Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50\n    \n\n        Parmantier & Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier & Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23628), on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}